Creative Biomart Announces Commercial Agreement for Services of Biosimilar Cell Lines Manufacturing

Creative Biomart announced today that it has signed a commercial agreement for contract manufacturing pharmaceutical biosimilar cell lines for a big pharma company.

New York, NY, November 10, 2013 --(PR.com)-- Creative Biomart, the global company offering technologies and services for the rapid development of high-performance stable cell lines, announced today that it has signed a commercial agreement for contract manufacturing pharmaceutical biosimilar cell lines with its proprietary gene screening and amplification system for a big pharma company.

Dr. Chen, president of Creative Biomart, commented “We are so glad and proud to announce that the major pharma company has selected Creative Biomart’s services and technology for their Stage II trial shortly after recombinant protein purchase. We will apply our unique platforms in combination with our technology portfolio and manufacture from Shirley, New York site.”

Creative Biomart will complete the process development and commercial manufacturing for the products. The project will be performed at the R&D site in New York. The commercial demand will be met from the production line.

Final terms were not disclosed according the responding department.

For more information
Creative Biomart Marketing Sector
Email: info@creative-biomart.com
Phone: 1-631-559-9269
Referring Web: http://www.creativebiomart.net/recombinantproteins-Biosimilar-Cell-Lines.htm
Contact
Creative Biomart
Caroline Green
1-516-855-7709
http://www.creativebiomart.net/
ContactContact
Categories